Health Advocacy
NEWHow WikiLeaks Is Changing The Face
Of Journalism
Jane Bryant
The One Click Group NEW
Courage Is Contagious
How To Whistleblow Safely
Julian Assange
WikiLeaks One Click Launches
Support
Dr Sarah Myhill
Campaign
By Jane Bryant Digital Economy Bill
Threatens One Click
By Jane Bryant UPDATED
March 2010
One Click
Freedom
Of Information
UK Police Harassment
In The Internet Era Barbara Loe Fisher
Interview
NVIC Conference
Style, Gonads
Brass Ovaries
By Jane Bryant New Journalism
Challenging
Status Quo
By Jane Bryant
NVIC Conference
USA How The
Judicial Review
Of The CFS/ME
NICE Guidelines
Was Lost
Jane Bryant
The One Click Group The BMJ
Vaccines Propaganda
Professor
David Salisbury
And
Trimedia
Public Relations David Southall
"A Very
Dangerous Doctor"
Panorama swims
with sharks
Lisa Blakemore Brown Dr David Salisbury
Ooops!
Never Mind Me,
I'm Basil Fawlty! ONE CLICK RESPONSE
David Salisbury
Vaccine Litigation Biomedical Test
For ME/CFS Announced
Dr Sarah Myhill
MB BS The Politics
And Commerce
Of Autism
By Lisa Blakemore Brown
Psychologist Poling
Vaccine/Autism Case
Mitochondrial Disfunction
ME/CFS Patients One Click Response
NICE Guidelines One Click Report
Gibson Inquiry How To Solve A Problem Like ME/CFS:
Why The Gibson Report Has Failed Patients Realpolitik and ME
By Martin J. Walker The Consensus Report
Family Law Reform Canadian Definition of ME-CFS The Weird World of Wikipedia
By Martin J. Walker Click here to email us your opinions.
| [Previous] | [Next] |
| [Previous] | [Next] |
| Ties To GlaxoSmithKline Led To Favorable Killer Avandia Drug Studies | ||
 February 25th, 2010 Ties To Glaxo Led To Favorable Avandia Studies By Ed Silverman  An analysis of authors who published reports on GlaxoSmithKline’s Avandia diabetes pill shows that those with ties to industry were more likely to conclude the drug didn’t increase the risk of myocardial infarction compared with authors with no industry ties, according to a study presented at the American College of Preventive Medicine annual meeting, TheHeart.org reports. The analysis, which was presented as a poster by Mohammed Hassan Murad of the Mayo Clinic, reviewed 202 articles that addressed the possible association between MI risk and Avandia in diabetes patients. Articles selected for review addressed the findings of two studies, a meta-analysis of small trials and a subsequent larger trial, that contributed to the controversy, TheHeart.org writes. Of the papers evaluated, 107, or 53 percent, included a conflict-of-interest statement and 90, or 45 percent, had a conflicting financial relationship. Among authors who concluded Avandia doesn’t increase the risk of MI, 91 percent had financial ties to makers of diabetes meds and 86 percent had relationships with Glaxo, TheHeart.org continues. Among authors of articles offering unfavorable reviews, only 25 percent had financial relationships with makers of diabetes meds and 18 percent had relationships with Glaxo that were disclosed in the papers. Murad noted that in some cases, when an online search was conduced for some authors, they found some who listed financial conflicts in other publications that weren’t disclosed in their Avandia paper. “Disclosure rates of conflicting financial relationships were misleadingly low despite their clear and strong linkage with authors’ expressed views,” Murad noted. “These findings underscore the need for further progress in reform for the scientific record to be trusted. The quality of care patients receive is clearly affected by these findings.” ************* Related Links: * FDA Pharma Reps Diddle As Glaxo's Avandia Drug Causes Multiple Deaths Vera Hassner Sharav, AHRP ************* |
||
|
||
